Docirbrutinib not checked

Carna Biosciences, Inc. · AS-1763

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.-brutinib: Bruton's tyrosine kinase inhibitors WHO name stem
Tested for
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Main trialPhase 1
“This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.”In the company’s words, NCT05602363 on ClinicalTrials.gov
Other names
AS-1763

Other drugs for B-cell Malignancy

All 47 drugs for B-cell Malignancy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Sep 2027 AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Docirbrutinib

Following is part of Solo: you see every change to Docirbrutinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in